Do young, early-stage breast cancer patients with pCR to chemoimmunotherapy still benefit from PMRT?
If a patient in her 30s with a cT2N0 triple negative breast cancer has a pathologic complete response (pCR) after chemo/immunotherapy at the time of mastectomy, do you still feel they would benefit from PMRT?
1 Answer
Mednet MemberInvited Expert
Radiation Oncology · Mayo Clinic Hospital
Answered on
As far as I am aware, it is not part of the usual practice to offer PMRT in the setting of T2N0 TN breast cancer. Though I think it may be considered as an "out of the box" recommendation in the setting of multiple high-risk features (larger T2 size, poor response to neo-adjuvant tx, LVI, young age,...
Join for free or sign in to see the full answer